Eddie Brock is getting the Venom symbiote back, and Marvel says it happens in a new ongoing series launching in October 2026, after the Queen in Black crossover wraps. That is the blunt headline version of today’s Comic-Con reveal, but the real business question is what “back to basics” continuity means for everything publishing-adjacent: what readers expect next, how other characters get re-staged, and how Marvel sequences big event-to-monthly transitions.

The new Venom series will be helmed by writer Charles Soule and artist Tommaso Bianchi, with cover artist Davide Paratore. Marvel also walked the audience through what Venom #1 is trying to do narratively: after years apart, “once again THEY ARE VENOM,” with Eddie determined to become the ultimate host for the symbiote and “be the hero he knows he can be,” pushing back against other super heroes. In other words, the editorial intent is not subtle. Eddie is returning as the central host, and the book positions that reunion as both catharsis and conflict, at least in terms of how the symbiote relationship will be treated.

Why this matters beyond comic fans arguing in comment threads: Marvel is treating continuity like a product roadmap. Previously, the symbiote passed from Eddie to his son Dylan and then to Mary Jane Watson. Bringing Eddie back is a reset switch, and those switches have ripple effects in reader behavior and in the way Marvel allocates attention across titles. Fans who got comfortable with the “new host” era are now being asked to re-adjust their mental model. That may sound like pure storytelling, but in publishing terms it is a demand on engagement, subscriptions, and trade paperback sales timing.

Marvel is pairing this Venom shift with a parallel plan for Mary Jane. The official plan at the panel is that MJ will star in a new series of her own, resuming a more normal status quo again. The description is pointed: Friendly Neighborhood Mary Jane sees MJ return to her Hollywood career as a producer and butt heads with the Chameleon. That matters because it reduces the risk that Mary Jane fans feel abandoned when the symbiote role changes hands. Instead, Marvel is segmenting audiences. Venom delivers symbiote-first spectacle and identity reunion. Friendly Neighborhood Mary Jane delivers character-forward normalcy and a different kind of threat.

Production details also tell a story. Venom #1 is written by Charles Soule, and the art is by Tommaso Bianchi, with Davide Paratore on covers. Friendly Neighborhood Mary Jane is a five-issue series, written by Ashley Allen and drawn by Phil Noto. From an operator’s view, this is Marvel balancing star power and pipeline stability. Soule’s “Star Wars” credit signals mainstream genre competence. Bianchi’s “Thunderbolts” credit signals action and tonal control. Noto’s “Daredevil & Echo” credit signals character intensity. The point is that Marvel is not just rebooting Eddie. It is staffing the book to land the emotional “two becoming one” promise.

There is also the scheduling logic. Venom #1 debuts in October 2026, followed by Friendly Neighborhood Mary Jane in November. That sequencing is not random. It creates a two-month handoff where “big symbiote story” momentum can bleed into “character and workplace drama” momentum, keeping the reader pipeline warm. It also gives Marvel room to close out Queen in Black cleanly, rather than forcing a simultaneous re-host transition while the event storyline is still in motion. If Queen in Black is serving as the major gravity well, Venom is positioned to become the escape trajectory as soon as the event completes.

At Comic-Con, Marvel also revealed new crossover specials tied to Phillip Kennedy Johnson’s Infernal Hulk series. This lineup includes Infernal Hulk vs. Wolverine #1, Infernal Hulk vs. Fantastic Four #1, Infernal Hulk vs. Spider-Man #1, and Infernal Hulk vs. Avengers #1. All are written by Johnson and are intended to help lay the foundation for the upcoming Hulk War event. This is important for executives and board-level decision-makers because it demonstrates an event scaffolding approach. Big event to big event is one way to go. Another is to use a set of smaller crossovers as preheating devices, building a narrative runway so the eventual flagship event has “on-ramp” moments that convert casual readers into committed ones.

From a broader market lens, Marvel’s approach reflects how modern media groups manage IP continuity across many SKUs. Monthly comics are increasingly tied to expectations that are set by movies, series, games, and even toy lines. The fact that IGN also highlighted Hasbro’s Legend of Zelda figures and early details on new Maximum X-Men comics within the SDCC hub underscores the cross-category attention spans at play. When audiences are scanning at convention speed, Marvel’s job is to make each reveal feel consequential and time-stamped. Eddie becoming Venom again in October 2026 is exactly that kind of time-stamped promise.

Strategically, this is a move that tells peers in publishing-adjacent industries something: if you want to move the market, you do not just “add a new book.” You reset identity stakes, coordinate side-series to reduce churn, and align staffing and release windows to match the cadence of your biggest story events. For decision-makers, the question is whether the continuity reset drives incremental demand and whether the cross-series routing keeps readers from bouncing between titles when the symbiote goes back to Eddie. Marvel is betting that the answer is yes, and the calendar suggests they plan to cash that bet starting October 2026.